FindTrial
Sign In

Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19)

Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029658
Enrollment
Unknown
Registered
2020-02-09
Start date
2020-02-10
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

experimental group:high-fow therapy by nasal cannulae (HFNC)
control group:bag- valve mask oxygenation (SMO)

Sponsors

Central Theater General Hospital of PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Eligible patients were adults ((aged 18-80 years); 2. Were identified as laboratory-confirmed 2019-nCoV infection; 3. Those who need intubation in ICU, and with no severe hypoxemia.

Exclusion criteria

Exclusion criteria: 1. Intubation required immidiately in case of cardiac arrest or asphyxia; 2. Pregnancy, severe chronic respiratory, uncontrolled gastric reflux disease and any nasopharyngeal anatomical obstacle; 3. Those patients has intubated in ICU.

Design outcomes

Primary

MeasureTime frame
the lowest SpO2 during intubation;—

Secondary

MeasureTime frame
the incidence of hypoxia;the times of intubation;Jaw thrust maneuver;Length of stay in ICU;Death;the during of intubation;—

Countries

China

Contacts

Public ContactLi Bixi

Central Theater General Hospital of PLA

bxlee@sohu.com+86 13397192089

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026